Ipca Laboratories Ltd

Meeting Details

• Date and time: August 14, 2026, 15:30 IST.
• Type and mode: Earnings conference call, virtual online event.
• Organizer: DAM Capital Advisors Limited.
• Recording: Conference is being recorded; transcript available.

Participants

• Key company participants: Managing Director; Corporate Counsel and Company Secretary.

Purpose

• Purpose: discuss Q1 FY27 earnings and business update.

Additional Notes

• Transcript and recording are available for investor access.

Meeting Details

• Date and time: 14 August 2026, 15:30 IST.
• Type and mode: Earnings conference call (virtual).
• Event: Ipca Q1 FY27 Earnings Conference Call; organised by DAM Capital Advisors.
• Recording: Conference call was recorded.

Participants

• Managing Director: A.K. Jain.
• Corporate Counsel & Company Secretary: Harish Kamath.
• Moderator: Nitin Agarwal, DAM Capital Advisors Limited.

Purpose

• Discuss Q1 FY27 earnings and business update.
• Investor Q&A session following presentation.

Additional Notes

• Transcript of the conference call is included in the filing.

Meeting Details

• Date and time: 14 August 2026, 15:30 IST.
• Type and mode: group conference call, virtual (audio).
• Organiser: Ipca Laboratories Limited.
• Purpose: discuss Q1 FY27 earnings and business update.

Participants

• Key company participant: Corporate Counsel & Company Secretary.

Availability

• Audio recording of conference call available.

AGM Details

• AGM held on 13 August 2026 at 3:30 PM IST via VC/OAVM.
• Record date for voting: 7 August 2026.
• Total shareholders on record: 85,465.
• Remote e-voting window: 10–12 August 2026.

Key Resolutions

• Resolution 1: Adoption of Audited Financial Statements and Consolidated Statements for FY2026.
• Resolution 2: Declaration of dividend on equity shares.
• Resolution 3: Re-appointment of Ajit Kumar Jain as Director by rotation.
• Resolution 4: Re-appointment of Pranay Godha as Director by rotation.
• Resolution 5: Re-appointment of Prashant Godha as Executive Director; remuneration.
• Resolution 6: Ratification of remuneration to ABK & Associates for cost audit 2026-27.

Voting Results

• Resolution 1: Passed; 99.98% in favour, 0.02% against.
• Resolution 2: Passed; 100.00% in favour.
• Resolution 3: Passed; 99.41% in favour.
• Resolution 4: Passed; 99.45% in favour.
• Resolution 5: Passed; 90.26% in favour.
• Resolution 6: Passed; 100.00% in favour.

Dividend

• Dividend on equity shares was declared.

Director Changes

• Ajit Kumar Jain re-appointed as Director by rotation.
• Pranay Godha re-appointed as Director by rotation.
• Prashant Godha re-appointed as Executive Director for five years from Aug 16, 2026.

Auditor Remuneration

• Remuneration for ABK & Associates (Cost Auditor) ratified for 2026-27.

Financial results and approvals

• Standalone Q1 FY27 unaudited revenue from operations: 2119.24 cr; total income: 2136.66 cr.
• Standalone Q1 FY27 PAT: 373.29 cr; EPS: 14.71.
• Consolidated Q1 FY27 revenue from operations 2788.10 cr; PAT 422.81 cr; EPS 15.84.
• Standalone EBITDA margin 26.27%; Consolidated margin 22.88%.
• Board approved Standalone and Consolidated Q1 FY27 unaudited results on Aug 13, 2026.
• Independent auditor's review: unmodified; no material misstatement.

Major corporate actions

• Amalgamation with Krebs Biochemicals & Industries Ltd approved; appointed date April 1, 2026.
• Awaiting consents; no effect in unaudited results.
• Consolidated Q1 FY27 Labour Codes exceptional item: 45.82 cr.
• Standalone Labour Codes exceptional item: 30.42 cr (FY2026).
• Consolidated full-year exceptional items total 86.43 cr, including EC settlement 58.26 cr and disposal gain 17.65 cr.

Regulatory & audit notes

• IND AS results prepared; Regulation 33 LODR compliance.
• Auditor’s review: unmodified.
• Krebs amalgamation details disclosed; pending consents.
• Press release issued with Q1 highlights.

Meeting Details

• Date and time: Friday, 14 August 2026, 15:30–16:30 IST.
• Type and mode: group conference call (virtual teleconference) for investors and analysts.
• Event/organiser: Dam Capital Advisors Ltd.

Participants

• Company participants: Managing Director and Corporate Counsel & Company Secretary.

Purpose

• Purpose: Discuss Q1 FY27 earnings and business update.

Meeting Details

• Date: 13 August 2026; Time: not disclosed; Location: not disclosed.

Key Agenda Items

• Consider standalone unaudited Q1 FY2026-27 financial results (period ended 30 June 2026).
• Consider consolidated unaudited Q1 FY2026-27 financial results (period ended 30 June 2026).

Other Notes

• Trading window closed 1 July 2026 to 15 August 2026 (48 hours after results declaration).

AGM notice and Annual Report access

• 76th AGM on 13 August 2026 at 3:30 p.m. IST via VC/OAVM.
• Annual Report 2025-26 accessible online; link/path shared for unregistered-email shareholders.
• Access notice sent to members without registered emails; cut-off date 10 July 2026.
• Annual Report link: www.ipca.com, path: investors-annual-reports.

KYC and dematerialisation reminders for physical holders

• Reminder to update KYC per SEBI Master Circular 2024; PAN, address, mobile, bank, and signature required.
• Electronic payments for physical folios require updated PAN and contact details.
• Nomination and KYC formats ISR-1/2/3, SH-13/14 available on registrar site.
• Registrar: MUFG Intime India; service helpdesk link and phone for updates.